<DOC>
	<DOCNO>NCT02298335</DOCNO>
	<brief_summary>This study ass efficacy safety 8-weeks full-dose induction protocol ( prednisone 1mg/kg , maximum 60mg/day ) protract taper protocol treatment adult idiopathic nephrotic syndrome .</brief_summary>
	<brief_title>Glucocorticoid Treatment Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study</brief_title>
	<detailed_description>In full-dose induction period , patient scheme visit 4th 8th week , protract tapering period 10th , 22nd , 42nd 66th week . If patient reach complete remission within 4 week , prednisone may decrease 6th week , otherwise keep course 8th week . All patient reach complete remission shift protract tapering period follow prednisone withdrawal , except case relapse drop study . If proteinuria reappears someone , angiotensin-converting enzyme inhibitor（ACEI） angiotensin receptor blocker（ARB） consider combination , premise blood pressure affordable .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Patients sign write informed consent form Age 1865 year , female male Patients diagnosis nephrotic syndrome ( proteinuria ≥3.5 g/24h , serum albumin ≤30g/L ) , Pathological diagnosis minimal change disease ( MCD ) , focal segmental glomerulosclerosis ( FSGS ) podocyte disease Serum creatinine &lt; 3mg/dl ( 265.2umol/L ) , estimate glomerular filtration rate ( eGFR ) less 30 ml/min.1.73 m2 Patients n't sign write informed consent form Patients receive fulldose prednisone treatment 2 week , pulse methylprednisolone ( &gt; 7.5mg/kg.day ) within 2 week Patients take immunosuppressant within 3 month , Cyclosporine A , Tacrolimus , Mycophenolate Mofetil , Cyclophosphamide , Leflunomide etc . Patients impaired liver function , Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) twice normal upper limit , viral hepatitis B hepatitis B e antigen ( HBeAg ) positive hepatitis B virus DNA ( HBVDNA ) reduplicative Patients contraindication glucocorticoid , example diabetes , obesity ( BMI &gt; 28kg/m2 disease onset ) , femoral head necrosis , active infection . Patients family history kidney disease Patients definite secondary fact disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prednisone</keyword>
	<keyword>idiopathic nephrotic syndrome</keyword>
	<keyword>prospective</keyword>
</DOC>